15.24
+0.59(+4.03%)
Currency In USD
| Previous Close | 14.65 |
| Open | 14.79 |
| Day High | 15.58 |
| Day Low | 14.78 |
| 52-Week High | 17.75 |
| 52-Week Low | 6.99 |
| Volume | 1.57M |
| Average Volume | 2.49M |
| Market Cap | 1.81B |
| PE | -13.14 |
| EPS | -1.16 |
| Moving Average 50 Days | 14.62 |
| Moving Average 200 Days | 11.97 |
| Change | 0.59 |
If you invested $1000 in Arcutis Biotherapeutics, Inc. (ARQT) since IPO date, it would be worth $699.08 as of May 05, 2025 at a share price of $15.24. Whereas If you bought $1000 worth of Arcutis Biotherapeutics, Inc. (ARQT) shares 3 years ago, it would be worth $725.02 as of May 05, 2025 at a share price of $15.24.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025
GlobeNewswire Inc.
Apr 17, 2025 12:00 PM GMT
WESTLAKE VILLAGE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will
Arcutis Announces Chief Financial Officer Transition
GlobeNewswire Inc.
Apr 10, 2025 8:30 PM GMT
Latha Vairavan Latha Vairavan, currently vice president and controller, will assume the role of CFO and join the executive team. WESTLAKE VILLAGE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commer
Arcutis and Padagis Agree to Stay Patent Lawsuit
GlobeNewswire Inc.
Apr 02, 2025 5:16 PM GMT
WESTLAKE VILLAGE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, is pleased to announce that